- Scancell Holdings has provided an update on SCIB1, the lead programme from the company's ImmunoBody platform, and its future plans for a US clinical trial in malignant melanoma.

"We are pleased to report that most patients with resected disease enrolled in the SCIB1 clinical trial are still alive and without disease recurrence, including the majority of patients who were previously undergoing continuation treatment," said CEO Richard Goodfellow.

"As previously announced, our next study, which will be in the US, will assess the potential for an increase in response rate in patients with malignant melanoma when treated with SCIB1 and a checkpoint inhibitor. We remain on track to submit the IND for this study in 3Q17."

Story provided by